Latin America Angina Pectoris Drugs Market

The size of the Latin American Angina Pectoris Drugs Market is estimated to grow at a steady CAGR between 2022 to 2027.

The increasing prevalence of angina, easy availability of therapeutic drugs for angina pectoris, high healthcare spending, the launch of new products, and the increased awareness of various cardiovascular disorders in developing countries are projected to drive the growth of the Latin American angina pectoris drugs market during the studied period. According to the WHO, cardiovascular disease is the most common cause of death worldwide, with about 17.78 million deaths reported in 2016, which represents almost 31.56% of all deaths worldwide. Therefore, the high prevalence of angina pectoris has been of great medical and social concern, representing a market opportunity for market players in Latin American regions. Trends in antianginal drug development include synergistic combinations, ongoing clinical trials, and other drug developments, including new routes of administration, etc. In addition, clinical trials are underway to discover new combinations for the treatment of angina pectoris, which will help to improve the quality of life of patients and minimize health costs.

According to the World Survey on Aging 2019, the world population aged 65 and over was 710 million in 2020. The elderly population is expected to double to 1.58 billion people by 2050. This population is more susceptible to cardiovascular diseases such as arrhythmias and angina pectoris due to the loss of elasticity of blood vessels and clogged arteries. The growing burden due to sedentary lifestyle practices has a direct impact on the socio-economic status of the society, which gets overwhelmed with healthcare costs and management. The development of new drugs offers additional therapeutic options in angina pectoris.

However, factors such as low per capita health expenditure and the high cost of therapeutic procedures will have a negative impact on this studied market. According to a study published by the Brazilian Journal of Cardiovascular Surgery in 2018, the average total cost for treatment of angina pectoris is estimated to be approximately USD 5,000. Additionally, side effects of diltiazem consumption, long-term drug use, and increased competition in the generic version of drugs challenge the market during the forecast period.

This research report on the Latin America angina pectoris drugs market has been segmented and sub-segmented into the following categories:

By Therapeutic Class: 

• Beta-Blockers
• Calcium Antagonists
• Anticoagulants
• Anti-Platelets
• Others    

By Country: 

• Mexico
• Brazil
• Argentina
• Chile
• Rest of Latin America

Brazil dominated the Latin American angina pectoris drugs market due to the well-developed healthcare industry, increasing healthcare spending, and a huge cardio-vascular disease patient population. Although, according to a recent study, it was estimated that more than half of the adult population of around 51.23% in Latin America was overweight, these obese people are more at risk for angina.

Most of the region's market can be attributed to growing healthcare spending and stable economies in Argentina, Chile, Peru, and Bolivia. Therefore, these places are anticipated to grow at a steady CAGR during the analysis period. In addition, major international market players such as Merck & Co., Inc. and Baxter in the region are driving the market's growth. Meanwhile, some regions such as Columbia, Venezuela, and Uruguay will have the smallest share of the Latin American angina pectoris drugs market due to the presence of poor economies, low awareness, and strict government policies.

Mexico is the second-largest market for Latin America angina pectoris drugs market. Factors such as the availability of funds for research, the growing number of obese and patients, increasing healthcare spending, and favorable government policies drive the growth of this market during the forecast period. In addition, other developed economies in Latin America are focusing on expanding their pharmaceutical and healthcare industry with a growing focus on treating life-style related disorders such as diabetics, coronary artery disease and angina pectoris, etc.

KEY MARKET PLAYERS:

Some of the major companies dominating the market by their products and services include Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Merck & Co. Inc., Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Ark Therapeutics Group plc, Torrent Pharmaceuticals Limited, Circ Pharma Limited, HUYA Bioscience International LLC, Lacer S.A., Viromed Co. Ltd., and Baxter Healthcare Corporation.